etoricoxib / Generic mfg. - LARVOL DELTA

Etoricoxib-Induced Fixed Erythema. (PubMed, J Clin Med) - "Patch testing was negative, while oral challenge confirmed etoricoxib-induced FDE; celecoxib was subsequently evaluated as a potential safe alternative. This case underscores the importance of an integrated diagnostic approach-including careful history, clinical examination, and confirmatory testing-to accurately diagnose delayed cutaneous drug reactions and to identify safe therapeutic options for patients."

Journal • Cardiovascular • Dermatology • Endocrine Disorders • Hypertension • Immunology • Pruritus • Renal Calculi • CD8

Case Report: A potential novel treatment for drug-induced acute interstitial nephritis: Benralizumab. (PubMed, Front Immunol) - "Two weeks prior to presentation, he was prescribed etoricoxib for back pain. The administration of benralizumab-an anti-CD125 antibody-resulted in rapid and complete recovery of kidney function. This case report highlights the potential role of benralizumab in the treatment of drug-induced interstitial nephritis with eosinophiluria."

Journal • Acute Kidney Injury • Back Pain • Cardiovascular • Hypertension • Musculoskeletal Pain • Nephrology • Pain • Renal Disease

Exploratory study on the efficacy of Lingze mixture in gouty arthritis rats and preliminary analysis of its potential mechanisms via transcriptome sequencing. (PubMed, Sci Rep) - "Animals were treated with LM at low, medium, or high doses, with etoricoxib as a positive control...Our findings confirm the anti-gout efficacy of LM in vivo and provide preliminary evidence suggesting its action may be associated with the modulation of the TLR4/MyD88/NF-κB pathway. This study offers valuable mechanistic clues and a foundation for further in-depth investigation into LM's mode of action."

Journal • Preclinical • Gout • Immunology • Inflammation • Inflammatory Arthritis • Rheumatology • MYD88 • TLR4

Herbal analgesic patches versus NSAIDs in soft tissue injury management: real-world comparative effectiveness from a 35-center chinese prospective cohort of 1378 participants. (PubMed, Int J Surg) - "GTP is a safe NSAIDs alternative, especially for patients with comorbidities. Monotherapy or a 2-week SCI-to-GTP transition is recommended because of the lack of combination synergy."

HEOR • Journal • Real-world evidence • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain

Clinical phenotype and genetic analysis of a patient with Progressive pseudorheumatoid dysplasia due to compound heterozygous variants of CCN6 gene and a literature review (PubMed, Zhonghua Yi Xue Yi Chuan Xue Za Zhi) - "The c.348C>A and c.676G>C compound heterozygous variants of the CCN6 gene probably underlay the pathogenesis of PPRD in this patient. Above finding has enriched the mutational spectrum of PPRD and provided a basis for the clinical diagnosis and genetic counseling."

Journal • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Prophylactic effects of non-steroidal anti-inflammatory drugs on heterotopic ossification after total hip arthroplasty: a Bayesian network meta-analysis of randomized controlled trials using cumulative logistic regression. (PubMed, BMC Musculoskelet Disord) - "Considering the efficacy of preventing HO following THA observed in our research, together with analgesic effect and gastrointestinal tract safety from previous literature, etoricoxib 90 mg/d is recommended as the optimal choice for patient undergoing THA. More head-to-head and long-term studies are needed."

Journal • Retrospective data • Review • Gastrointestinal Disorder • Orthopedics • Pain

Etoricoxib and its hidden risks: a case-based review of dermatological, hematological, and cardiovascular complications. (PubMed, EXCLI J) - "See also the graphical abstract(Fig. 1)."

Journal • Review • Atrial Fibrillation • Cardiovascular • Dermatology • Hematological Disorders • Hypertension • Immunology • Steven-Johnson Syndrome • Thrombocytopenia

Oral and Vaginal Ulcers Associated with Etoricoxib (ACAAI 2025) - "With Etoricoxib’s widespread and sometimes unsupervised use, the risk of missed or delayed diagnosis increases. Recent pharmacovigilance data highlight this issue, underscoring the need for heightened clinical suspicion and timely drug withdrawal to avoid complications."

Ankylosing Spondylitis • Dermatology • Gout • Immunology • Osteoarthritis • Pruritus • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Investigating Sulfotransferase Mediated Drug Interactions of Ethinylestradiol using a Physiologically Based Pharmacokinetic Model. (PubMed, AAPS J) - "The developed PBPK models for etoricoxib and ziritaxestat can be used in future applications as probe SULT1E1 precipitants. Incorporation of SULT metabolism into the EE PBPK model may support a more comprehensive assessment of the DDI liability of investigational drugs that affect multiple EE metabolic pathways."

Journal • PK/PD data • CYP2C9 • CYP3A4 • SULT1E1 • UGT1A1

The Effect of Prophylactic Use of NSAIDs on Acute Phase Reactions Induced by First-Time Zoledronic Acid Treatment for Osteoporosis. (PubMed, Ann Pharmacother) - "Prophylactic NSAIDs significantly reduce zoledronic acid-induced APRs, especially pain, but have no significant effect on preventing fever. The 3 NSAIDs also have comparable efficacy."

Journal • Musculoskeletal Pain • Osteoporosis • Pain • Rheumatology

Pruritic eruption in a young woman with fever. (PubMed, Skin Health Dis) - "She was eventually diagnosed with persistent pruritic eruption (PPE) of adult-onset Still disease (AOSD) and was treated with oral etoricoxib with resolution of her fever and symptoms...This is in contrast to other conditions such as cutaneous lupus or dermatomyositis, where the dyskeratotic keratinocytes are found in the lower epidermis instead. This case highlights the importance of clinicopathological correlation and recognition of PPEs in AOSD in view of the associated poorer prognosis due to associated conditions such as secondary macrophage activation syndrome."

Journal • Alopecia • Cutaneous Lupus Erythematosus • Dermatomyositis • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Lupus • Musculoskeletal Pain • Myositis

Lipid Raft Membrane Interactivity Correlating with Cyclooxygenase-2 Selectivity of Non-Steroidal Anti-Inflammatory Drugs. (PubMed, Membranes (Basel)) - "Conventional NSAIDs (diclofenac, ibuprofen, indomethacin, aspirin, and flurbiprofen) and Coxibs (lumiracoxib, etoricoxib, celecoxib, valdecoxib, and rofecoxib) decreased membrane fluidity, whereas Oxicams (meloxicam, piroxicam, tenoxicam, and lornoxicam) increased. Under inflammatory acidic conditions, the lipid raft membrane interactivity of NSAIDs was more likely to correlate with cyclooxygenase-2 selectivity than the reference membrane interactivity. It is hypothesized that NSAIDs may interact with lipid raft membranes to induce membrane fluidity changes with the potency corresponding to cyclooxygenase-2 inhibition, disrupting the structural and functional integrity of lipid rafts to affect the activity of cyclooxygenase-2 localized in lipid rafts, resulting in cyclooxygenase-2 selective inhibition."

Journal

Generalized bullous fixed pigmented erythema mimicking toxic epidermal necrolysis: About two-cases (EADV 2025) - "Case 2: A 51-year-old man, with a history of schizophrenia treated with levomepromazine and diazepam for 10 years, presented with generalized erosions that developed within 24 hours after taking omeprazole. The drugs most frequently implicated in FPE include nonsteroidal anti-inflammatory drugs (such as etoricoxib), antibiotics (sulfonamides, tetracyclines), anticonvulsants, and, more rarely, proton pump inhibitors (omeprazole). This warrants heightened vigilance when prescribing these medications, especially in cases of recurrent lesions at the same sites."

Clinical • CNS Disorders • Dermatology • Psychiatry • Schizophrenia • Steven-Johnson Syndrome

A Menstrual-Linked Rash That Wasn't: Etoricoxib-Induced Fixed Drug Eruption Confirmed by Lesional Patch Testing (EADV 2025) - "This case highlights the importance of thorough medication history-taking—including over-the-counter and international drug use—in patients with atypical rashes. The cyclical timing of the eruptions in this patient was a misleading association, delaying the correct diagnosis. Lesional patch testing proved essential in uncovering FDE when standard testing was inconclusive."

Dermatology • Immunology

Nationwide Etoricoxib Injection Clinical Experience (NICE) 2.0: Assessing Real-World Effectiveness and Tolerability of Etoricoxib Injection in Acute Pain Management in Both Inpatient and Outpatient Settings. (PubMed, Cureus) - "IM etoricoxib demonstrated rapid and sustained pain relief with excellent tolerability across diverse patient populations."

Journal • Real-world evidence • Back Pain • Musculoskeletal Pain • Pain

A prospective case-control study: Analysis of the analgesic effect of acetaminophen-mannitol injection after endoscopic lumbar discectomy. (PubMed, J Int Med Res) - "The observation group underwent treatment with acetaminophen-mannitol for pain relief, whereas the control group was administered oral etoricoxib and intravenous mannitol...The observation group had a similar time to start walking and length of hospital stay as the control group. The total incidence rate of adverse reactions was zero.ConclusionAcetaminophen-mannitol injection has a good analgesic effect after endoscopic lumbar discectomy, which is beneficial for accelerating the postoperative recovery of patients."

Journal • Musculoskeletal Diseases • Orthopedics • Pain

Preparation and Evaluation of Amorphous Solid Dispersion of Etoricoxib, Employing A Fast Approach for Polymer Selection. (PubMed, Antiinflamm Antiallergy Agents Med Chem) - "The solubility increased from 99.08 to 296.8 μg/ml and the dissolution rose from 69.32% to 98.07%. These findings suggest that the kneading method and Poloxamer successfully produced amorphous solid dispersions of etoricoxib with significantly enhanced solubility and dissolution properties, potentially improving its bioavailability."

Journal • Cardiovascular • Inflammation • Pain

D-optimal design-based optimization of Etoricoxib cubogel for management of arthritis; In vitro and in vivo Evaluation. (PubMed, Pharm Dev Technol) - "Anti-inflammatory study confirmed enhanced (P < 0.05) anti-inflammatory activity of Et cubogel as compared to Et gel. Hence, present study presents Et cubgel formulation as an anti-inflammatory remedy."

Journal • Preclinical • Immunology • Osteoarthritis • Pain • Rheumatology

Postpartum lumbopelvic pain could be SAPHO syndrome: a case report. (PubMed, Front Immunol) - "After combined treatment with Tofacitinib citrate tablets and Etoricoxib tablets, all the pain symptoms disappeared. For postpartum patients with concurrent palmoplantar scaling and recurrent LPP unresponsive to treatment, clinicians should consider SAPHO syndrome as a potential diagnosis."

Journal • Acne Vulgaris • Gynecology • Immunology • Musculoskeletal Pain • Pain • Psoriasis

Selective Cyclooxygenase-2 Inhibitors in Preclinical Rodent Models of Depression and Post-traumatic Stress Disorder: A Systematic Review of Behavioral, Neuroinflammatory, and Molecular Mechanisms. (PubMed, ACS Chem Neurosci) - "COX-2 inhibitors such as celecoxib, meloxicam, and etoricoxib reduced forced swim test immobility by approximately 40% and increased sucrose preference by 25-30%, effects comparable to or exceeding SSRIs. While findings consistently support these agents' antidepressant- and anxiolytic-like efficacy in chronic stress models, their translational potential is limited by male-restricted samples (91% of studies), underreporting of effect sizes, and a scarcity of long-term durability assessments. These results support continued investigation of COX-2 inhibitors as adjunctive treatments in stress-related psychiatric disorders, with an emphasis on sex-stratified analyses and standardized behavioral and molecular reporting."

Journal • Preclinical • Review • CNS Disorders • Depression • Inflammation • Mental Retardation • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry • BDNF • GFAP • IL6 • PTGS2 • TNFA

Nanocrystals as a promising approach for enhancing solubility and dissolution of etoricoxib using Box-Behnken design. (PubMed, Sci Rep) - "Additionally, the nanocrystals exhibited rapid dissolution profile, achieving 91.49 ± 0.01% drug release within 5 min. These results suggest that using nanocrystals to improve the aqueous solubility and dissolution of medications with poor solubility is a potential strategy."

Journal

Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial. (PubMed, Rheumatol Ther) - P2 | "Compared with etoricoxib, firsekibart provides superior target joint pain relief and is well-tolerated in patients with frequent gout flares."

Clinical • Head-to-Head • Journal • P2 data • Dyslipidemia • Gout • Hypertriglyceridemia • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Rheumatology

Metallaphotoredox-Catalyzed Cross-Electrophile Couplings of Aryl Chlorides and Alkyl Halides: Harnessing the σ-Donor/π-Acceptor Synergy of a 2-(1H-Imidazol-2-yl) pyridine Ligand. (PubMed, Angew Chem Int Ed Engl) - "This protocol enabled the efficient late-stage diversification of the drugs Me-fenofibrate, indomethacin, and etoricoxib to enhance their sp3-rich complexity. Using an equimolar ratio of substrates, this methodology facilitated a decagram XEC in continuous flow, showcasing the applicability of the method for large scale synthesis."

Journal

Exploring the Cardiovascular Safety Profile of Ibuprofen: Insights from EudraVigilance Database. (PubMed, Pharmaceuticals (Basel)) - "Stroke was reported for ibuprofen with a lower probability compared with etoricoxib (ROR: 0.34; 95% CI: 0.21-0.55), celecoxib (ROR: 0.07; 95% CI: 0.06-0.10), meloxicam (ROR: 0.25; 95% CI: 0.14-0.43), acetylsalicylic acid (ROR: 0.07; 95% CI: 0.05-0.09), and ibuprofen/pseudoephedrine (ROR: 0.11; 95% CI: 0.05-0.25). Myocardial infarction was reported as being more probable for ibuprofen than ketoprofen (ROR: 2.31; 95% CI: 1.57-3.40) or nimesulide (ROR: 2.43; 95% CI: 1.25-4.73). Overall, according to our study, the probability of reported cardiovascular adverse reactions is lower than those determined for the rest of the NSAIDs; however, taking into consideration the inherent limitations of the study, further clinical investigations would contribute to a better understanding of the cardiovascular safety of ibuprofen."

Journal • Cardiovascular • Gastrointestinal Disorder • Hematological Disorders • Hypertension • Myocardial Infarction • Thrombosis

DoE-Optimized Minitabs: Fabricating a Promising Modified-Release Sprinkle Formulation. (PubMed, Recent Adv Drug Deliv Formul) - "As the formulation was designed using a model drug, further investigations with other drugs can also be done with relevant changes in the optimized formulation. In summary, it can also be utilized as a platform for developing modified-release sprinkle formulations of other drugs."

Journal • Gastrointestinal Disorder • Pediatrics